BMS 753

Cat. No.:	HY-107395
CAS No.:	215307-86-1
Molecular Formula:	$C_{21}H_{21}NO_4$
Molecular Weight:	351.4
Target:	RAR/RXR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (142.29 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.8458 mL	14.2288 mL	28.4576 mL
5 mM	0.5692 mL	2.8458 mL	5.6915 mL
10 mM	0.2846 mL	1.4229 mL	2.8458 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.92 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.92 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMS 753 is an isotype-selective retinoic acid receptor α (RARα) agonist, with a K_i of 2 nM[1].

IC_{50} & Target

RARα[1]

In Vitro

BMS 753 results in low levels of RARβ transcripts in WT cells, $RAR\gamma^{-/-}$, but not activates in $RARa^{-/-}$ cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. M Géhin, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29.

[2]. R Taneja, et al. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12): 6

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA